Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Luboshitz

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Thyroid : Official Journal of the American Thyroid Association|November 24, 1999
Treatment of antithyroid drug-induced agranulocytosis by granulocyte colony-stimulating factor: a case of primum non nocereD Hirsch, J Luboshitz, I Blum
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven)G Kenet, A Lubetsky, J Luboshitz, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
A novel Phe171Cys mutation in integrin alpha causes Glanzmann thrombasthenia by abrogating alphabeta complex formationN Rosenberg, M Landau, J Luboshitz, et al.
Refu'At Ha-Peh Veha-Shinayim (1993)|April 7, 2004
[Platelet rich plasma (PRP) as adjuvant tool for bone augmentation]J Luboshitz, U Berger, O Yaari, et al.
FEBS Letters|June 20, 2000
Protein disulfide isomerase mediates integrin-dependent adhesionJ Lahav, N Gofer-Dadosh, J Luboshitz, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 13, 2000
Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VIIG Kenet, A Lubetsky, S Gitel, et al.
Thrombosis and Haemostasis|May 25, 2001
Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndromeJ Luboshitz, A Lubetsky, L Schliamser, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 30, 2002
Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experienceA Lubetsky, U Martinowitz, J Luboshitz, et al.
Journal of Internal Medicine|April 17, 1999
Cutaneous necrosis as a terminal paraneoplastic thromboembolic event in a patient with non-Hodgkin's lymphomaJ Luboshitz, O Bairey, D Blickstein, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 3, 2009
Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitorsG Kenet, A Lubetsky, J Luboshitz, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Thyroid : Official Journal of the American Thyroid Association|November 24, 1999
Treatment of antithyroid drug-induced agranulocytosis by granulocyte colony-stimulating factor: a case of primum non nocereD Hirsch, J Luboshitz, I Blum
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven)G Kenet, A Lubetsky, J Luboshitz, et al.
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
A novel Phe171Cys mutation in integrin alpha causes Glanzmann thrombasthenia by abrogating alphabeta complex formationN Rosenberg, M Landau, J Luboshitz, et al.
Refu'At Ha-Peh Veha-Shinayim (1993)|April 7, 2004
[Platelet rich plasma (PRP) as adjuvant tool for bone augmentation]J Luboshitz, U Berger, O Yaari, et al.
FEBS Letters|June 20, 2000
Protein disulfide isomerase mediates integrin-dependent adhesionJ Lahav, N Gofer-Dadosh, J Luboshitz, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 13, 2000
Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VIIG Kenet, A Lubetsky, S Gitel, et al.
Thrombosis and Haemostasis|May 25, 2001
Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndromeJ Luboshitz, A Lubetsky, L Schliamser, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 30, 2002
Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experienceA Lubetsky, U Martinowitz, J Luboshitz, et al.
Journal of Internal Medicine|April 17, 1999
Cutaneous necrosis as a terminal paraneoplastic thromboembolic event in a patient with non-Hodgkin's lymphomaJ Luboshitz, O Bairey, D Blickstein, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 3, 2009
Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitorsG Kenet, A Lubetsky, J Luboshitz, et al.
Pageof 2